Literature DB >> 20200551

Association of resistin and adiponectin with different clinical blood pressure phenotypes.

C Thomopoulos1, M Daskalaki, O Papazachou, N Rodolakis, A Bratsas, D P Papadopoulos, M V Papavasileiou, D Perrea, T Makris.   

Abstract

We investigated whether the resistin (Res) and adiponectin (Adp) levels are associated with different clinical blood pressure (BP) phenotypes. Among 465 consecutive never-treated white subjects, we excluded those with diabetes mellitus; impaired glucose metabolism; history of any cardiovascular disease or other concurrent medical condition; secondary hypertension; ongoing vasoactive treatment. Three separate clinic BP measurements and ambulatory BP monitoring were implemented to divide 328 subjects (aged 48±6 years; 172 males) into hypertensives (n=105), masked hypertensives (n=41), white-coat hypertensives (n=52) and normotensives (n=130). Participants underwent echocardiography and oral glucose tolerance testing, whereas, from fasting venous blood samples metabolic profile, plasma Res and Adp levels were assessed. Hypertensives and masked hypertensives showed higher log(10)(Res) and lower log(10)(Adp) levels compared with normotensives, whereas white-coat hypertensives had similar levels of these adipokines compared with normotensives. Common correlates for both of the adipokines were 24-h systolic BP, standing/sitting difference of both diastolic BP and heart rate, and waist circumference. Hypertensive and masked hypertensive compared with normotensive phenotype were independently associated with log(10)(Res) with odds ratios of 1.24 (1.08-1.44), and 1.16 (1.09-1.34) and log(10)(Adp) with 0.74 (0.65-0.87), and 0.81 (0.67-0.95), respectively. Increased Res and decreased Adp plasma levels are associated with out-of-clinic hypertension, whereas they did not determine white-coat hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200551     DOI: 10.1038/jhh.2010.22

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  12 in total

Review 1.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

2.  Single nucleotide polymorphism-single nucleotide polymorphism interactions among inflammation genes in the genetic architecture of blood pressure in the Framingham Heart Study.

Authors:  Jacob J Basson; Lisa de Las Fuentes; Dabeeru C Rao
Journal:  Am J Hypertens       Date:  2014-07-25       Impact factor: 2.689

3.  The association of plasma resistin with dietary sodium manipulation, the renin-angiotensin-aldosterone system, and 25-hydroxyvitamin D3 in human hypertension.

Authors:  Anand Vaidya; Luminita Pojoga; Patricia C Underwood; John P Forman; Paul N Hopkins; Gordon H Williams; Jonathan S Williams
Journal:  Clin Endocrinol (Oxf)       Date:  2011-03       Impact factor: 3.478

4.  Metabolic risk factors and masked hypertension in the general population: the Finn-Home study.

Authors:  M-Ra Hänninen; T J Niiranen; P J Puukka; A M Jula
Journal:  J Hum Hypertens       Date:  2014-01-02       Impact factor: 3.012

Review 5.  Vitamin D and vascular disease: the current and future status of vitamin D therapy in hypertension and kidney disease.

Authors:  Anand Vaidya; John P Forman
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

6.  Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers.

Authors:  Erieta Kollari; Ioanna Zografou; Christos Sampanis; Vasilios G Athyros; Triantafyllos Didangelos; Christos S Mantzoros; Asterios Karagiannis
Journal:  Hormones (Athens)       Date:  2021-10-30       Impact factor: 2.885

7.  Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.

Authors:  Cia-Hin Lau; Sekaran Muniandy
Journal:  Cardiovasc Diabetol       Date:  2011-01-21       Impact factor: 9.951

Review 8.  Association between serum resistin concentration and hypertension: A systematic review and meta-analysis.

Authors:  Yuxiang Zhang; Yixing Li; Lin Yu; Lei Zhou
Journal:  Oncotarget       Date:  2017-06-20

Review 9.  Linking resistin, inflammation, and cardiometabolic diseases.

Authors:  Hyeong Kyu Park; Mi Kyung Kwak; Hye Jeong Kim; Rexford S Ahima
Journal:  Korean J Intern Med       Date:  2017-02-16       Impact factor: 2.884

Review 10.  Resistin, an Adipokine with Non-Generalized Actions on Sympathetic Nerve Activity.

Authors:  Emilio Badoer; Samin Kosari; Martin J Stebbing
Journal:  Front Physiol       Date:  2015-11-10       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.